: By acquiring GW, Jazz Pharmaceuticals significantly reduced its reliance on its flagship narcolepsy drug, Xyrem . The combined company now has a robust portfolio across neuroscience and oncology.
If you are looking to buy stock in , it is important to know that as of April 28, 2026, the company no longer trades under its own ticker symbol. It was fully acquired by Jazz Pharmaceuticals in May 2021 for approximately $7.2 billion. buy stock in gw pharmaceuticals
Investment Rationale for GW Pharmaceuticals (via Jazz Pharmaceuticals) It was fully acquired by Jazz Pharmaceuticals in
: The acquisition included GW’s cannabinoid product platform and clinical-stage programs for additional indications such as autism, schizophrenia, and multiple sclerosis-related spasticity. The company took on substantial debt to finance the $7
While the GW Pharmaceuticals platform adds significant value, an investment in Jazz Pharmaceuticals carries its own risks. The company took on substantial debt to finance the $7.2 billion acquisition, leading to a temporary increase in leverage. Potential investors should monitor the company's progress in paying down this debt and the continued clinical trial success of its pipeline.